Form 8-K - Current report:
SEC Accession No. 0001437749-22-019949
Filing Date
2022-08-11
Accepted
2022-08-11 09:05:39
Documents
15
Period of Report
2022-08-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20220810_8k.htm   iXBRL 8-K 28852
2 EXHIBIT 99.1 ex_410564.htm EX-99.1 17065
7 panbela01.jpg GRAPHIC 6944
  Complete submission text file 0001437749-22-019949.txt   194351

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbla-20220811.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20220811_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20220811_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20220811_pre.xml EX-101.PRE 11688
9 EXTRACTED XBRL INSTANCE DOCUMENT pbla20220810_8k_htm.xml XML 2553
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

EIN.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 221153928
SIC: 2834 Pharmaceutical Preparations